

- **Name:** Dae Ho Lee
 - **Current Position & Affiliation:** Professor, University of Ulsan College of Medicine Asan Medical Center
 - **Country:** Korea
-

• Educational Background:

1987.3. ~ 1989.2. Pre-Medicine, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea

1989.3. ~ 1994.2. M.D. College of Medicine, Seoul National University, Seoul, Republic of Korea

1999.3. ~ 2001.2. Master of Science, Postgraduate School, Seoul National University, Seoul, Republic of Korea

2002. 9. ~ 2007.2. Ph.D Postgraduate School, Seoul National University, Seoul, Republic of Korea

• Professional Experience:

2002. 4 ~ 2006. 2. Medical Oncologist, Center for Specific Organs Cancer, National Cancer Center Hospital, Goyang, Gyeonggi-do, Republic of Korea

2003. 9 ~ 2006. 2. Medical Oncologist, Center for Lung Cancer, National Cancer Center Hospital, Goyang, Gyeonggi-do, Republic of Korea

2006. 3 – 2006. 8 Instructor, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

2006. 9. ~ 2011. 9. Assistant Professor, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

2011. 10 – 2017. 9. Associate Professor, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

2017.10 ~ present Professor, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

• Professional Organizations:

Member, Korean Medical Association

Member, Korean Association of Internal Medicine

Member, Korean Cancer Association

Member, Korean Society of Medical Oncology

Member, Korean Cancer Study Group

Member, Korean Association for Lung Cancer

Member, Korean Association of Institutional Review Board

Member, International Association for the Study of Lung Cancer

Member, American Society of Clinical Oncology

Member, American Association for Cancer Research

Member, European Society for Medical Oncology

Main Scientific Publications:

- Seo S, Moon Y, Choi J, Yoon S, Jung KH, Cheon J, Kim W, Kim D, Lee CH, Kim SW, Park KS, **Lee DH**. The GTP binding activity of transglutaminase 2 promotes bone metastasis of breast cancer cells by downregulating microRNA-205. Am J Cancer Res. 2019 Mar 1;9(3):597-607
- **Lee DH**, Tsao MS, Kambartel KO, Isobe H, Huang MS, Barrios CH, Khattak A, de Marinis F, Kothari S, Arunachalam A, Cao X, Burke T, Valladares A, de Castro J. Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PivOTAL observational study. PLoS One. 2018 Aug 27;13(8):e0202865
- Wu YL, Zhang L, Kim DW, Liu X, **Lee DH**, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, Chia V, Glaser S, Pultar P, Zhao S, Peng B, Akimov M, Tan DSW. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 Nov 1;36(31):3101-3109
- **Lee DH**. Practical issues of biomarker-assisted targeted therapy in precision medicine and immuno-oncology era. ESMO Open. 2018 Jun 12;3(Suppl 1):e000370. doi: 10.1136/esmoopen-2018-000370. eCollection 2018.
- Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, **Lee DH**, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. J Clin Oncol. J Clin Oncol. 2018 Sep 10;36(26):2693-2701
- **Lee DH**, Isobe H, Wirtz H, Aleixo SB, Parente P, de Marinis F, Huang M, Arunachalam A, Kothari S, Cao X, Donnini N, Woodgate AM, de Castro J. Health care resource use among patients with advanced non-small cell lung cancer: the PivOTAL retrospective observational study. BMC Health Serv Res. 2018 Mar 1;18(1):147.